drug
upadacitinib tartrate ER
Marketedupdated 5mo agoby $ABBV AbbVie Inc.
Approvedannual revenue · 2024–2024peak $6.0B
community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
all catalysts(19)
approval · 19
Aug 16, 2019
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jul 10, 2020
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 2, 2021
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jan 14, 2022
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Mar 16, 2022
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 29, 2022
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Oct 21, 2022
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 10, 2023
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
May 18, 2023
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jun 22, 2023
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Nov 14, 2023
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Mar 26, 2025
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 28, 2025
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Aug 12, 2025
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Oct 10, 2025
approval
$ABBV262.82+1.11%
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Trials studying upadacitinib tartrate ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 26, 2027
204 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (74)
- Mar 9, 2038method-of-use (U-3624)US 11564922
- Mar 9, 2038method-of-use (U-3624)US 11564922
- Mar 9, 2038method-of-use (U-3624)US 11564922
- Mar 9, 2038method-of-use (U-3341)US 11607411
- Mar 9, 2038method-of-use (U-3341)US 11607411
- Mar 9, 2038method-of-use (U-3341)US 11607411
- Oct 17, 2036formulationUS 10202393
- Oct 17, 2036formulationUS 10344036
- Oct 17, 2036formulationUS 10519164
- Oct 17, 2036method-of-use (U-3298)US 10550126
- Oct 17, 2036method-of-use (U-3255)US 10597400
- Oct 17, 2036formulationUS 10730883
- Oct 17, 2036compositionUS 10981923
- Oct 17, 2036compositionUS 10981923
- Oct 17, 2036compositionUS 10981923
- Oct 17, 2036formulationUS 10981924
- Oct 17, 2036formulationUS 10981924
- Oct 17, 2036method-of-use (U-3298)US 10995095
- Oct 17, 2036compositionUS 11186584
- Oct 17, 2036compositionUS 11186584
- Oct 17, 2036compositionUS 11186584
- Oct 17, 2036formulationUS 11198697
- Oct 17, 2036formulationUS 11198697
- Oct 17, 2036formulationUS 11198697
- Oct 17, 2036method-of-use (U-3275)US 11365198
- Oct 17, 2036method-of-use (U-3371)US 11512092
- Oct 17, 2036method-of-use (U-3371)US 11524964
- Oct 17, 2036method-of-use (U-3255)US 11535624
- Oct 17, 2036method-of-use (U-3298)US 11535625
- Oct 17, 2036method-of-use (U-3298)US 11535626
- Oct 17, 2036compositionUS 11661425
- Oct 17, 2036compositionUS 11661425
- Oct 17, 2036compositionUS 11661425
- Oct 17, 2036compositionUS 11680069
- Oct 17, 2036compositionUS 11680069
- Oct 17, 2036compositionUS 11680069
- Oct 17, 2036compositionUS 11718627
- Oct 17, 2036compositionUS 11718627
- Oct 17, 2036compositionUS 11718627
- Oct 17, 2036method-of-use (U-3298)US 11767326
- Oct 17, 2036method-of-use (U-3298)US 11767326
- Oct 17, 2036compositionUS 11773105
- Oct 17, 2036compositionUS 11773105
- Oct 17, 2036compositionUS 11773105
- Oct 17, 2036method-of-use (U-3371)US 11773106
- Oct 17, 2036formulationUS 11780847
- Oct 17, 2036method-of-use (U-3371)US 11780848
- Oct 17, 2036formulationUS 11787815
- Oct 17, 2036method-of-use (U-3255)US 11795175
- Oct 17, 2036method-of-use (U-3298)US 11976077
- Oct 17, 2036method-of-use (U-3946)US 11993605
- Oct 17, 2036method-of-use (U-3487)US 11993606
- Oct 17, 2036formulationUS 12077545
- Oct 17, 2036formulationUS 12077545
- Oct 17, 2036formulationUS 12077545
- Oct 17, 2036formulationUS 12091415
- Oct 17, 2036formulationUS 12103933
- Oct 17, 2036formulationUS 12110297
- Oct 17, 2036compositionUS 12110298
- Oct 17, 2036compositionUS 12110298
- Oct 17, 2036compositionUS 12110298
- Oct 17, 2036formulationUS 12116373
- Oct 17, 2036formulationUS 12134621
- Oct 17, 2036method-of-use (U-3945)US 12365689
- Oct 17, 2036compositionUS 9951080
- Oct 17, 2036compositionUS 9951080
- Oct 17, 2036compositionUS 9951080
- Oct 17, 2036formulationUS 9963459
- Aug 16, 2033compositionUS RE47221
- Aug 16, 2033compositionUS RE47221
- Aug 16, 2033compositionUS RE47221
- Jan 15, 2031compositionUS 89626294.3y
- Jan 15, 2031compositionUS 89626294.3y
- Jan 15, 2031compositionUS 89626294.3y
FDA exclusivities (13)
- Apr 26, 2031ODE-481Orphan Drug (7y)4.6y
- Apr 26, 2031ODE-481Orphan Drug (7y)4.6y
- Apr 26, 2031ODE-481Orphan Drug (7y)4.6y
- Apr 28, 2028I-966Indication (3y)1.6y
- Apr 26, 2027I-946Indication (3y)204d
- Apr 26, 2027I-946Indication (3y)204d
- Apr 26, 2027NPPNew Product (3y)204d
- Apr 26, 2027NPPNew Product (3y)204d
- Apr 26, 2027I-946Indication (3y)204d
- Apr 26, 2027NPPNew Product (3y)204d
- May 18, 2026I-919Indication (3y)
- May 18, 2026I-919Indication (3y)
- May 18, 2026I-919Indication (3y)
News(10)
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- North Immunology joins biotech reverse merger boom with Aethlon dealArmed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.biopharma_dive · 16d ago
- North Immunology goes public via reverse merger as eczema drug heads toward clinicNorth Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.fiercebiotech · 17d ago
- Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 winsSpyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.fiercebiotech · 26d ago
- FDA green lights Priovant drug for rare skin diseaseLisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.biopharma_dive · 1mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 2mo ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 2mo ago
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.fiercebiotech · 2mo ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that